The Emerging Role of Biomarkers in Atrial Fibrillation

Canadian Journal of Cardiology

Volumn 29, Issue 10, 2013, Pages 1181-1193

  Kornej, Jelena ^a,b   Apostolakis, Stavros ^a   Bollmann, Andreas ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATECEGATRAN METOXIL; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; D DIMER; EDOXABAN; GELATINASE B; INTERLEUKIN 6; NATRIURETIC FACTOR; PADGEM PROTEIN; SELECTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADIPOSE TISSUE; ANTICOAGULATION; CARDIAC IMAGING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMODYNAMIC STRESS; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LONGITUDINAL STUDY; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF PUMP CORONARY SURGERY; OPEN STUDY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SINUS RHYTHM; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE VOLUME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; HUMANS; INCIDENCE; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH;

EID: 84884595106     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.04.016     Document Type: Review

References (124)

1. Healey J.S., Parkash R., Pollak T., Tsang T., Dorian P. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. Can J Cardiol 2011, 27:31-37.
2. Daoud E.G., Bogun F., Goyal R., et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996, 94:1600-1606.
3. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997, 96:1180-1184.
4. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
5. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
6. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
7. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
8. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013, 34:1475-1480.
9. Hijazi Z., Oldgren J., Andersson U., et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 2012, 125:1605-1616.
10. Wolf P.A., Abbot R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
11. Enta K., Iwade K., Aosaki M., Uchida T., Kasanuki H. Predictive value of coagulative molecular markers for thromboembolism in patients with nonvalvular atrial fibrillation: Prospective five-year follow-up study [in Japanese]. JCardiol 2004, 44:223-232.
12. Heeringa J., Conway D.S., van der Kuip D.A., et al. Alongitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam study 1990-1999. JThromb Haemost 2006, 4:1944-1949.
13. Nozawa T., Inoue H., Hirai T., et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006, 109:59-65.
14. Ferro D., Loffredo L., Polimeni L., et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 2007, 27:2763-2768.
15. Lip G.Y., Patel J.V., Hughes E., Hart R.G. High-sensitivity c-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007, 38:1229-1237.
16. Girerd N., Pibarot P., Fournier D., et al. Middle-aged men with increased waist circumference and elevated c-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur Heart J 2009, 30:1270-1278.
17. Kurl S., Ala-Kopsala M., Ruskoaho H., et al. Plasma N-terminal fragments of natriuretic peptides predict the risk of stroke and atrial fibrillation in men. Heart 2009, 95:1067-1071.
18. Crandall M.A., Horne B.D., Day J.D., et al. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive c-reactive protein incrementally and independently. Pacing Clin Electrophysiol 2009, 32:648-652.
19. Pinto A., Tuttolomondo A., Casuccio A., et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond) 2009, 116:781-789.
20. Schachner T., Wiedemann D., Fetz H., Laufer G., Kocher A., Bonaros N. Influence of preoperative serum n-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients. Clinics (Sao Paulo) 2010, 65:1239-1245.
21. Smith J.G., Newton-Cheh C., Almgren P., et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. JAm Coll Cardiol 2010, 56:1712-1719.
22. Sadanaga T., Kohsaka S., Mitamura H., Ogawa S. Elevated b-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 2011, 26:530-535.
23. Roldan V., Marin F., Muina B., et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. JAm Coll Cardiol 2011, 57:2496-2504.
24. van den Bos E.J., Constantinescu A.A., van Domburg R.T., Akin S., Jordaens L.J., Kofflard M.J. Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. Eur Heart J 2011, 32:611-617.
25. Roldan V., Marin F., Diaz J., et al. High sensitivity cardiac troponin t and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. JThromb Haemost 2012, 10:1500-1507.
26. Hermida J., Lopez F.L., Montes R., Matsushita K., Astor B.C., Alonso A. Usefulness of high-sensitivity c-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2012, 109:95-99.
27. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009, 373:155-166.
28. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. NEngl J Med 2012, 367:625-635.
29. Roldan V., Marin F., Fernandez H., et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013, 111:1159-1164.
30. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: Implications for thromboprophylaxis and bleeding risk. JAm Coll Cardiol 2011, 57:1339-1348.
31. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013, 127:224-232.
32. Banerjee A., Fauchier L., Vourc'h P., et al. Renal impairment and ischaemic stroke risk assessment in patients with atrial fibrillation: the loire valley atrial fibrillation project. JAm Coll Cardiol 2013, 61:2079-2087.
33. Roldán V., Marín F., Manzano-Fernández S., et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. Thromb Haemost 2013, 109:956-960.
34. Mitchell L.B. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention and treatment of atrial fibrillation following cardiac surgery. Can J Cardiol 2011, 27:91-97.
35. Pfister R., Scholz M., Wielckens K., Erdmann E., Schneider C.A. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004, 6:289-293.
36. Nielsen O.W., McDonagh T.A., Robb S.D., Dargie H.J. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. JAm Coll Cardiol 2003, 41:113-120.
37. Ata Y., Turk T., Ay D., et al. Ability of b-type natriuretic peptide in predicting postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Heart Surg Forum 2009, 12:E211-E216.
38. Iskesen I., Eserdag M., Kurdal A.T., Cerrahoglu M., Sirin B.H. Preoperative NT-proBNP levels: a reliable parameter to estimate postoperative atrial fibrillation in coronary artery bypass patients. Thorac Cardiovasc Surg 2011, 59:213-216.
39. Amar D., Zhang H., Shi W., et al. Brain natriuretic peptide and risk of atrial fibrillation after thoracic surgery. JThorac Cardiovasc Surg 2012, 144:1249-1253.
40. Cuthbertson B.H., Amiri A.R., Croal B.L., et al. Utility of b-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. Br J Anaesth 2007, 99:170-176.
41. Winkel T.A., Schouten O., Hoeks S.E., Verhagen H.J., Bax J.J., Poldermans D. Prognosis of transient new-onset atrial fibrillation during vascular surgery. Eur J Vasc Endovasc Surg 2009, 38:683-688.
42. Leal J.C., Petrucci O., Godoy M.F., Braile D.M. Perioperative serum troponin I levels are associated with higher risk for atrial fibrillation in patients undergoing coronary artery bypass graft surgery. Interact Cardiovasc Thorac Surg 2012, 14:22-25.
43. Jogia P.M., Kalkoff M., Sleigh J.W., et al. NT-pro BNP secretion and clinical endpoints in cardiac surgery intensive care patients. Anaesth Intensive Care 2007, 35:363-369.
44. Martinez-Comendador J., Castano M., Mosquera I., et al. Cryoablation of atrial fibrillation in cardiac surgery: outcomes and myocardial injury biomarkers. JCardiothorac Vasc Anesth 2011, 25:1030-1035.
45. Lombardi F., Tundo F., Belletti S., Mantero A., Melzi D'eril G.V. C-reactive protein but not atrial dysfunction predicts recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. JCardiovasc Med (Hagerstown) 2008, 9:581-588.
46. Tveit A., Seljeflot I., Grundvold I., Abdelnoor M., Arnesen H., Smith P. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. Int J Cardiol 2009, 131:234-239.
47. Bartkowiak R., Wozakowska-Kaplon B., Janiszewska G. Plasma NT-proANP in patients with persistent atrial fibrillation who underwent successful cardioversion. Kardiol Pol 2010, 68:48-54.
48. Siu C.W., Watson T., Lai W.H., et al. Relationship of circulating endothelial progenitor cells to the recurrence of atrial fibrillation after successful conversion and maintenance of sinus rhythm. Europace 2010, 12:517-521.
49. Latini R., Masson S., Pirelli S., et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. JIntern Med 2011, 269:160-171.
50. Hussein A.A., Saliba W.I., Martin D.O., et al. Plasma b-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation 2011, 123:2077-2082.
51. Kalogeropoulos A.S., Tsiodras S., Rigopoulos A.G., et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord 2011, 11:77.
52. Alonso A., Tang W., Agarwal S.K., Soliman E.Z., Chamberlain A.M., Folsom A.R. Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: The ARIC study. Int J Cardiol 2012, 155:217-222.
53. Kornej J., Reinhardt C., Kosiuk J., et al. Response of high-sensitive c-reactive protein to catheter ablation of atrial fibrillation and its relation with rhythm outcome. PLoS One 2012, 7:e44165.
54. Wang W., Liu L., Li Y., Hu S.S., Song Y.H., Wang X. Does the expression of transforming growth factor beta-1 affect the outcome of the radiofrequency modified maze procedure in patients with rheumatic atrial fibrillation?. Tex Heart Inst J 2012, 39:17-23.
55. Kornej J., Reinhardt C., Kosiuk J., et al. Response of circulating heat shock protein 70 and anti-heat shock protein 70 antibodies to catheter ablation of atrial fibrillation. JTransl Med 2013, 11:49.
56. Krishnamoorthy S., Lim S.H., Lip G.Y. Assessment of endothelial (dys)function in atrial fibrillation. Ann Med 2009, 41:576-590.
57. Heppell R.M., Berkin K.E., McLenachan J.M., Davies J.A. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997, 77:407-411.
58. Feinberg W.M., Pearce L.A., Hart R.G., et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999, 30:2547-2553.
59. Conway D.S., Buggins P., Hughes E., Lip G.Y. Relationship of interleukin-6 and c-reactive protein to the prothrombotic state in chronic atrial fibrillation. JAm Coll Cardiol 2004, 43:2075-2082.
60. Choudhury A., Chung I., Blann A.D., Lip G.Y. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 2007, 131:809-815.
61. Choudhury A., Freestone B., Patel J., Lip G.Y. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis?. Chest 2007, 132:1913-1919.
62. Choudhury A., Chung I., Blann A.D., Lip G.Y. Platelet surface CD62p and CD63, mean platelet volume, and soluble/platelet p-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. JAm Coll Cardiol 2007, 49:1957-1964.
63. Sadanaga T., Kohsaka S., Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology 2010, 117:31-36.
64. Fu R., Wu S., Wu P., Qiu J. Astudy of blood soluble p-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace 2011, 13:31-36.
65. Yuce M., Cakici M., Davutoglu V., et al. Relationship between mean platelet volume and atrial thrombus in patients with atrial fibrillation. Blood Coagul Fibrinolysis 2010, 21:722-725.
66. Sugiura S., Fujii E., Senga M., Sugiura E., Nakamura M., Ito M. Clinical features of patients with left atrial thrombus undergoing anticoagulant therapy. JInterv Card Electrophysiol 2012, 34:59-63.
67. Mondillo S., Sabatini L., Agricola E., et al. Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 2000, 75:227-232.
68. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002, 106:1962-1967.
69. Conway D.S., Pearce L.A., Chin B.S., Hart R.G., Lip G.Y. Prognostic value of plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107:3141-3145.
70. Lip G.Y., Pearce L.A., Chin B.S., Conway D.S., Hart R.G. Effects of congestive heart failure on plasma von Willebrand factor and soluble p-selectin concentrations in patients with non-valvar atrial fibrillation. Heart 2005, 91:759-763.
71. Roldan V., Marin F., Garcia-Herola A., Lip G.Y. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res 2005, 116:321-325.
72. Freestone B., Lip G.Y., Chong A.Y., Nadar S., Lee K.W., Blann A.D. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb Haemost 2005, 94:702-706.
73. Varughese G.I., Patel J.V., Tomson J., Lip G.Y. Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation. Heart 2007, 93:495-499.
74. Freestone B., Chong A.Y., Nuttall S., Blann A.D., Lip G.Y. Soluble e-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007, 132:1253-1258.
75. Freestone B., Gustafsson F., Chong A.Y., et al. Influence of atrial fibrillation on plasma von Willebrand factor, soluble e-selectin, and n-terminal pro b-type natriuretic peptide levels in systolic heart failure. Chest 2008, 133:1203-1208.
76. Kaireviciute D., Blann A.D., Balakrishnan B., et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010, 104:122-127.
77. Kaireviciute D., Lip G.Y., Balakrishnan B., et al. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. JThromb Haemost 2011, 9:2345-2352.
78. Montaner J., Perea-Gainza M., Delgado P., et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008, 39:2280-2287.
79. Ezekowitz M.D., Reilly P.A., Nehmiz G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007, 100:1419-1426.
80. Li-Saw-Hee F.L., Blann A.D., Lip G.Y. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000, 31:828-833.
81. Lip G.Y., Rasmussen L.H., Olsson S.B., et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin k antagonists. Eur Heart J 2009, 30:2897-2907.
82. Lip G.Y., Rasmussen L.H., Olsson S.B., et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb Res 2011, 127:91-99.
83. Weitz J.I., Connolly S.J., Patel I., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104:633-641.
84. Connolly S.J., Eikelboom J., Dorian P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (EXPLORE-Xa). Eur Heart J 2013, 34:1498-1505.
85. Kamath S., Blann A.D., Lip G.Y. Platelets and atrial fibrillation. Eur Heart J 2001, 22:2233-2242.
86. Ha S.I., Choi D.H., Ki Y.J., et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets 2011, 22:408-414.
87. Yukiiri K., Hosomi N., Naya T., et al. Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke. BMC Neurol 2008, 8:45.
88. Okada Y., Shibazaki K., Kimura K., et al. Brain natriuretic peptide is a marker associated with thrombus in stroke patients with atrial fibrillation. JNeurol Sci 2011, 301:86-89.
89. Shibazaki K., Kimura K., Fujii S., Sakai K., Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 2012, 109:1303-1307.
90. Lip G.Y., Lane D., Van Walraven C., Hart R.G. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006, 37:2294-2300.
91. Kim S.K., Park J.H., Kim J.Y., et al. High plasma concentrations of transforming growth factor-beta and tissue inhibitor of metalloproteinase-1: potential non-invasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. Circ J 2011, 75:557-564.
92. Marin F., Roldan V., Climent V., Garcia A., Marco P., Lip G.Y. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke 2003, 34:1181-1186.
93. Kim S.K., Pak H.N., Park J.H., et al. Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace 2009, 11:1632-1638.
94. Wu C.H., Hu Y.F., Chou C.Y., et al. Transforming growth factor-β1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. Heart Rhythm 2013, 10:10-15.
95. Boos C.J., Anderson R.A., Lip G.Y. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 2006, 27:136-149.
96. Issac T.T., Dokainish H., Lakkis N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. JAm Coll Cardiol 2007, 50:2021-2028.
97. Liu T., Li G., Li L., Korantzopoulos P. Association between c-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. JAm Coll Cardiol 2007, 49:1642-1648.
98. Lellouche N., Sacher F., Wright M., et al. Usefulness of c-reactive protein in predicting early and late recurrences after atrial fibrillation ablation. Europace 2009, 11:662-664.
99. Mandal K., Torsney E., Poloniecki J., Camm A.J., Xu Q., Jahangiri M. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg 2005, 79:865-871. [discussion: 871].
100. St Rammos K., Koullias G.J., Hassan M.O., et al. Low preoperative hsp70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc Surg 2002, 10:228-232.
101. Hu Y.F., Yeh H.I., Tsao H.M., et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ Arrhythm Electrophysiol 2012, 5:334-340.
102. den Uijl D.W., Delgado V., Tops L.F., et al. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J 2011, 161:197-203.
103. Wozakowska-Kaplon B., Bartkowiak R., Grabowska U., Janiszewska G. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance. Kardiol Pol 2010, 68:781-786.
104. Yalta K., Yilmaz M.B., Turgut O.O., Tandogan I. Natriuretic peptides: useful biomarkers in predicting the possibility of restoration and maintenance of sinus rhythm in patients with atrial fibrillation undergoing cardioversion?. Int J Cardiol 2010, 145:233. [author reply: 234-5].
105. Abdelhadi R.H., Gurm H.S., Van Wagoner D.R., Chung M.K. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. Am J Cardiol 2004, 93:1176-1178.
106. Freestone B., Chong A.Y., Nuttall S., Lip G.Y. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble e-selectin levels. Thromb Res 2008, 122:85-90.
107. Freestone B., Chong A.Y., Blann A.D., Lip G.Y. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction. Thromb Res 2006, 118:479-485.
108. Akar J.G., Jeske W., Wilber D.J. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. JAm Coll Cardiol 2008, 51:1790-1793.
109. Marin F., Roldan V., Climent V.E., et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin d-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 2004, 90:1162-1166.
110. Frankel D.S., Vasan R.S., D'Agostino R.B., et al. Resistin, adiponectin, and risk of heart failure the framingham offspring study. JAm Coll Cardiol 2009, 53:754-762.
111. Filkova M., Haluzik M., Gay S., Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009, 133:157-170.
112. Kim M., Oh J.K., Sakata S., et al. Role of resistin in cardiac contractility and hypertrophy. JMol Cell Cardiol 2008, 45:270-280.
113. Rienstra M., Sun J.X., Lubitz S.A., et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham offspring study. Am Heart J 2012, 163:119-124.e111.
114. Gungor H., Ayik M.F., Kirilmaz B., et al. Serum resistin level as a predictor of atrial fibrillation after coronary artery bypass graft surgery. Coron Artery Dis 2011, 22:484-490.
115. Kinoshita T., Asai T., Suzuki T., Kambara A., Matsubayashi K. Preoperative hemoglobin a1c predicts atrial fibrillation after off-pump coronary bypass surgery. Eur J Cardiothorac Surg 2012, 41:102-107.
116. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. NEngl J Med 2004, 351:1296-1305.
117. Ananthapanyasut W., Napan S., Rudolph E.H., et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:173-181.
118. Go A.S., Fang M.C., Udaltsova N., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009, 119:1363-1369.
119. Guo Y., Wang H., Zhao X., et al. Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. Int J Cardiol 2013, [Epub ahead of print].
120. Lip G.Y. Does atrial fibrillation confer a hypercoagulable state?. Lancet 1995, 346:1313-1314.
121. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
122. de Vos C.B., Pisters R., Nieuwlaat R., et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. JAm Coll Cardiol 2010, 55:725-731.
123. Conway D.S., Buggins P., Hughes E., Lip G.Y. Prognostic significance of raised plasma levels of interleukin-6 and c-reactive protein in atrial fibrillation. Am Heart J 2004, 148:462-466.
124. Kirchhof P., Lip G.Y., Van Gelder I.C., et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011, 106:1012-1019.